Abstract: An embodiment of the present invention provides a method for manufacturing spherical metal powder, comprising the steps of: (a) forming a slurry by mixing ultra-fine raw metal with a binder and a solvent; (b) forming granular powders by granulating the slurry through spray drying; (c) adding a separating agent to prevent sintering between the granular powders; (d) forming spherical metal powder by continuously degreasing and sintering the granular powders; (e) adding a deoxidizer for high purity of the sintered spherical metal powder to carry out deoxidation treatment; and (f) removing the separating agent and an oxide from the deoxidized spherical metal powder.

Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.

Abstract: The present invention relates to a pyrrolobenzodiazepine dimer prodrug and a ligand-linker conjugate compound thereof, a composition containing these, and therapeutic use thereof particularly as an anticancer drug. The stability of the compounds themselves and the stability thereof in plasma are excellent and the compounds are advantageous in terms of manifestation of toxicity, and thus the compounds are industrially useful in that it is possible to target proliferative diseases such as cancer, to perform a specific treatment, to maximize the drug efficacy, and to minimize the occurrence of side effects.

Abstract: The present disclosure relates to pyrrolobenzodiazepine dimer prodrugs and ligand-linker conjugates thereof. The present disclosure also relates to compositions and uses of said prodrugs and conjugates.

Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Abstract: The present invention relates to a ligand-drug conjugate including a ligand; a linker that is connected to the ligand by a covalent bond and has a tris structure represented by a specific structural formula; and an active agent connected to the linker by a covalent bond. In the ligand-drug conjugate, the active agent is bound by the tris structure of the linker, and thus a greater number of active agents can be connected through one linker. Accordingly, a greater number of active agents per antibody binding can be delivered to the target cell, and the drug and/or toxin can stably reach the target cell and effectively exert the drug efficacy.

Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.

Abstract: The present disclosure relates to pyrrolobenzodiazepine dimer prodrugs and ligand-linker conjugates thereof. The present disclosure also relates to compositions and uses of said prodrugs and conjugates.

Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.

Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Abstract: Described herein are functional cell assays and methods for selecting a personalized anti-cancer treatment regimen that can improve treatment of cancer in a subject, identify resistance of the subject's cancer to one or more anti-cancer agents and/or validate the current drug treatment strategy.

Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.

Abstract: A paper sheet conveying apparatus and method for an image information processor in which a paper sheet with image information recorded thereon can be prevented from a skew carriage. The paper sheet conveying apparatus includes a driving motor which is controlled to be shifted from a forward revolution mode to a reverse revolution mode or vice versa. The paper conveying apparatus further includes a power cleaving means that selectively supplies the power to a first power transmitting system and to a second power transmitting system.

Abstract: A sheet conveying apparatus for an image information processor includes a driving apparatus having a sheet supply opening and a sheet discharge opening arranged above and below and in the same direction, and a registration roller, a delivery roller, a scan roller, and a delivery roller arranged in order along a sheet conveying path formed in an opening curve of a substantially C-shape. The driving apparatus drives the rollers in mutual operations with selective combinations according to a sheet conveying process, and includes a driving motor controlled to change driving modes in the forward and reverse directions, and a power switching device for selectively transferring a rotational force to first and second power transmission systems according to the driving modes of the driving motor, whereby changes in sheet conveying speeds are controlled to secure reliability in the skew-feed correction of a sheet when supplying a large capacity of sheets at a high speed, and to adjust image resolution by mode.

Abstract: A paper sheet conveying apparatus and method for an image information processor in which a paper sheet with image information recorded thereon can be prevented from a skew carriage. The paper sheet conveying apparatus includes a driving motor which is controlled to be shifted from a forward revolution mode to a reverse revolution mode or vice versa. The paper conveying apparatus further includes a power cleaving means that selectively supplies the power to a first power transmitting system and to a second power transmitting system.

Abstract: A paper sheet conveying apparatus and method for an image information processor in which a paper sheet with image information recorded thereon can be prevented from a skew carriage. The paper sheet conveying apparatus includes a driving motor which is controlled to be shifted from a forward revolution mode to a reverse revolution mode or vice versa. The paper conveying apparatus further includes a power cleaving means that selectively supplies the power to a first power transmitting system and to a second power transmitting system.

Abstract: A sheet conveying apparatus for an image information processor includes a driving apparatus having a sheet supply opening and a sheet discharge opening arranged above and below and in the same direction, and a registration roller, a delivery roller, a scan roller, and a delivery roller arranged in order along a sheet conveying path formed in an opening curve of a substantially C-shape. The driving apparatus drives the rollers in mutual operations with selective combinations according to a sheet conveying process, and includes a driving motor controlled to change driving modes in the forward and reverse directions, and a power switching device for selectively transferring a rotational force to first and second power transmission systems according to the driving modes of the driving motor, whereby changes in sheet conveying speeds are controlled to secure reliability in the skew-feed correction of a sheet when supplying a large capacity of sheets at a high speed, and to adjust image resolution by mode.

Abstract: A paper sheet conveying apparatus and method for an image information processor in which a paper sheet with image information recorded thereon can be prevented from a skew carriage. The paper sheet conveying apparatus includes a driving motor which is controlled to be shifted from a forward revolution mode to a reverse revolution mode or vice versa. The paper conveying apparatus further includes a power cleaving means that selectively supplies the power to a first power transmitting system and to a second power transmitting system.